Department of Psychiatry, Gil Medical Center and Gachon University College of Medicine, Incheon 21565, Korea.
Int J Mol Sci. 2020 Mar 20;21(6):2148. doi: 10.3390/ijms21062148.
The acute treatment duration for major depressive disorder (MDD) is 8 weeks or more. Treatment of patients with MDD without predictors of treatment response and future recurrence presents challenges and clinical problems to patients and physicians. Recently, many neuroimaging studies have been published on biomarkers for treatment response and recurrence of MDD using various methods such as brain volumetric magnetic resonance imaging (MRI), functional MRI (resting-state and affective tasks), diffusion tensor imaging, magnetic resonance spectroscopy, near-infrared spectroscopy, and molecular imaging (i.e., positron emission tomography and single photon emission computed tomography). The results have been inconsistent, and we hypothesize that this could be due to small sample size; different study design, including eligibility criteria; and differences in the imaging and analysis techniques. In the future, we suggest a more sophisticated research design, larger sample size, and a more comprehensive integration including genetics to establish biomarkers for the prediction of treatment response and recurrence of MDD.
重度抑郁症（MDD）的急性治疗期为 8 周或更长时间。对于没有治疗反应和未来复发预测因素的 MDD 患者的治疗，给患者和医生带来了挑战和临床问题。最近，许多神经影像学研究使用各种方法（如脑容积磁共振成像（MRI）、功能 MRI（静息状态和情感任务）、弥散张量成像、磁共振波谱、近红外光谱和分子成像（即正电子发射断层扫描和单光子发射计算机断层扫描））发表了关于 MDD 治疗反应和复发的生物标志物的研究。结果并不一致，我们假设这可能是由于样本量小；不同的研究设计，包括入选标准；以及成像和分析技术的差异。在未来，我们建议采用更复杂的研究设计、更大的样本量以及更全面的综合方法，包括遗传学，以建立 MDD 治疗反应和复发预测的生物标志物。
